HealthScience communications consultancy wins King’s Award
July 11, 2023 | AwardWinning, Awards, MedicalAffairs, MedicalCommunications, Publications
Oxford PharmaGenesis, the global HealthScience communications consultancy, was honoured on Friday 7 July, by a visit from King Charles III’s representative in Oxfordshire, Lord-Lieutenant Marjorie Glasgow BEM.
Oxford PharmaGenesis, the global HealthScience communications consultancy, was honoured last week, Friday 7 July, by a visit from King Charles III’s representative in Oxfordshire, Lord-Lieutenant Marjorie Glasgow BEM. Mrs Glasgow visited their head office just outside Oxford, UK, to present one of the first King’s Awards for Enterprise.
Announced in King Charles III’s coronation year, the King’s Award is the most prestigious business accolade in the UK. The King personally approves the list of award recipients, which recognizes just 148 companies this year. For Oxford PharmaGenesis, this completes a remarkable hat-trick, having secured the Queen’s Award for Enterprise in 2015 and in 2019.
These awards recognize the company’s excellence in international trade, and Oxford PharmaGenesis has doubled its exports roughly every 5 years since its foundation, with approximately 75% of the company’s work with clients in mainland Europe, North America and Asia-Pacific.
Launching with one employee in 1998, Oxford PharmaGenesis has grown to become the leading independent HealthScience consultancy, providing communications services to the healthcare industry, professional societies and patient groups in the UK and globally.
Over the past decade alone, the company’s overseas sales have risen from £5.2 million to £29.5 million. Over the same period, the number of full-time employees has risen from 83 in 2013 to more than 500 today. Oxford PharmaGenesis currently employs 436 people in the UK and a further 107 people across the USA, Europe and Australia.
The company’s top five markets are USA (37% of total sales), UK (23%), Switzerland (22%), Denmark (3%) and Sweden (3%).
Oxford PharmaGenesis CEO, Dr Chris Winchester said “This prestigious award recognizes the company’s growth in overseas revenue and profitability. Our unique culture brings out the best in our brilliant and talented team, who continue to develop and grow here with us, thanks to the opportunities we offer and our recognition as a ‘Great Place to Work’.
We already work with nine of the world’s 10 largest pharmaceutical companies and, based on our experience after securing similar recognition from the late Queen, we expect this award to open doors to many new relationships. Energized by this new recognition, we are pressing on with our mission of helping clients bring new treatments to patients with unmet clinical needs”.
Oxford PharmaGenesis COO, Dr Richard White said “The growth that this award recognizes has enabled us to invest in building a long-term sustainable future for the company, in developing innovative new services and expanding our environmental, social and governance activities (ESG). The King’s Award emblem will stand alongside the silver medal for ESG that we recently received from EcoVadis, the leading global ratings platform. We are committed to working with our loyal clients, partners and suppliers to deliver innovation and sustainability, partnering with charities, academic institutions and patient groups whenever possible”.
Company founder and Chairman, Dr Graham Shelton said “We’re thrilled to receive a King’s Award in the year we are celebrating both the King’s coronation and the company’s 25th anniversary. It was a particular joy for me to attend a reception for King’s Award winners hosted by King Charles III at Buckingham Palace last month.
Since launching Oxford PharmaGenesis in Oxford, UK, I have been proud of the virtuous circle that has seen talented people delivering high-quality services to our clients, resulting in sustained growth. We value our independent status, which helps us build trust between clients and colleagues, all of whom share our passion for providing better treatments to patients throughout the world”.
This content was provided by Oxford PharmaGenesis
Company Details
Latest Content from Oxford PharmaGenesis
ACCORD: new guideline to support consistent and complete reporting of consensus methods in biomedical research
Oxford PharmaGenesis has contributed to the development of the new ACCORD reporting guideline to help the medical and scientific communities to improve the reporting of research involving consensus methodologies.
HealthScience communications consultancy wins King’s Award
Oxford PharmaGenesis, the global HealthScience communications consultancy, was honoured on Friday 7 July, by a visit from King Charles III’s representative in Oxfordshire, Lord-Lieutenant Marjorie Glasgow BEM.
The MM+M Agency 100 report: Oxford PharmaGenesis is recognized as an industry leader for the third year running
We have scored a hat-trick, with media brand Medical Marketing and Media (MM+M) listing Oxford PharmaGenesis in its Agency 100 report for a third consecutive year.
Oxford PharmaGenesis wins King’s Award following rapid export growth
Oxford PharmaGenesis has been honoured with the first ever King’s Award for Enterprise, the most prestigious business award in the country.
Pharmaceutical companies reduce own greenhouse gas emissions, but action on supply chains needed
DPhil student, Dr Amy Booth (University of Oxford) and Oxford PharmaGenesis CEO, Dr Chris Winchester, have co-authored a new study published in the International Journal of Environmental Research and Public...
Ten unbeatable reasons to explore a career with Oxford PharmaGenesis in 2022
It’s a new year, and a time when many people reflect on whether their role is providing the opportunities, enjoyment and sense of purpose that they deserve. If this sounds...